SpainSpain

Spanish fair surpasses expectations

20.11.2008

Granada – “We’ve broken all records.” This was Jose Luis Jarcano’s (Genoma Espana) conclusion after the end of the 4th BioSpain in Granada, Spain’s 3rd largest bio­tech cluster. “BioSpain 2008 has attracted more exhibitors, professionals and international delegates than any of its predecessors,” said Jose Maria Fernendez, President of the co-organising Spanish Association of Bioenterprises (ASEBIO). “The numbers demonstrate that the sector is in good health.”
The three-day event surpassed the BioSpain 2006 held in Madrid. Many of the 162 exhibitors spoke of a “tremendous leap in quality”, because practically the entire domestic sector took part. A high-ranking scientific congress entitled “Biotech 2008”, organised by Spanish biotech society SEBIOT, spanned a wide spectrum of issues: from bio­chemical engineering to agri-food, industrial biotech to microbial genomics, biocatalysis to bioinformatics. A partnerning forum organised by the EBD group counted 1,000 face-to-face meetings. In addition, 5 out of the 28 biotechs presenting to international investors were rewarded at the end of BioSpain’s finance forum: SpinX (Switzerland), CelleriX (Spain), Alfama (Portugal), Amsterdam Molecular Therapies (Netherlands, and Sinali Seafields (US). A further highlight was a plenary lecture by Steven Burrill, head of an international investor group, who underlined that biotech as a enabling technology will penetrate medicine and many areas of daily life by 2020.
“Biotechnology in Spain is currently growing at a rate of more than 25% per year” in terms of sales and exports, employment and attraction of investments, said Science and Innovation Minister Cristina Garmendia at BioSpain’s inauguration. “This is much higher than average rates in the US and the rest of Europe.” Garmendia, a former president at Genetrix, also underlined the importance of internationalisation, which she said would be paid back in exports, alliances and foreign investment.

SpainSpain

01.10.2011

Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu...

SpainSpain

01.10.2011

Lisbon – A Portuguese-American research team has discovered an association between a variant in the gene DZIP1 and Parkinson’s disease (PD). The collaboration brought André Valente from the Biocant Biotechnology Innovation Center...

SpainSpain

29.09.2011

Granada - Alentia Biotech, a joint venture of Spanish pharmaceuticals companies Laboratorios Farmaceuticos Rovi SA and Ferrer, will invest €92m in the construction of a flu vaccines plant in Granada. The annual production...

SpainSpain

23.09.2011

Madrid - Spain unveiled a grand alliance between all stakeholders in biomedicine to foster innovation in the sector. Minister of Science and Innovation, Cristina Garmendia, met the representatives of institutions, public research...

Italy, SpainSpain

18.08.2011

Vinaros – The Italian company Transactiva failed to start a field trial of a genetically modified rice variant in southeastern Spain. Although the National Commission on Biosafety had approved the field trial, the Committee on...

SpainSpain

09.08.2011

Madrid/Ingelheim – Pharmaceutical company Boehringer Ingelheim has cleared the way for Spanish rival Almirall and ended a long-standing patent squabble, although the reconciliation was not exactly voluntary. Behind the scenes,...

SpainSpain

13.06.2011

Madrid – Spain is working to establish itself as a European hotspot for bio­energy production. The country’s Abengoa Bioenergia Nuevas Tecnologias, a subsidiary of Abengoa Bioenergy, will lead an international consortium in the...

SpainSpain

11.06.2011

Madrid – Agendas, working committees and associations in Europe’s biotechnology sector are not hard to find. Now the spanking new Spanish Biotech Platform (launched in May) has to show if it is more than just another extension of...

SpainSpain

06.02.2011

Madrid – Noscira, a Madrid-based company looking for Alzheimer treatments in marine life forms, raised a19m in a private placement of 3.8 million shares at EUR5 to existing and new investors. The main stakeholder is Zeltia S.A,...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/1/article/spanish-fair-surpasses-expectations.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4290.4%
  • CO.DON2.51 EUR191.9%
  • PAION2.43 EUR164.1%

FLOP

  • CYTOS0.25 CHF-93.9%
  • MEDIGENE4.53 EUR-69.2%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 01.09.2014


Current issue

All issues

Product of the week

Products